REFLUX ESOPHAGITIS
Clinical trials for REFLUX ESOPHAGITIS explained in plain language.
Never miss a new study
Get alerted when new REFLUX ESOPHAGITIS trials appear
Sign up with your email to follow new studies for REFLUX ESOPHAGITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New acid blocker takes on standard drug for Post-Surgery reflux
Disease control Recruiting nowThis study tests whether a newer acid-reducing drug, Vonaprazan, heals acid reflux better than the standard drug Esomeprazole in people who had POEM surgery for achalasia. About 300 adults with moderate to severe esophagitis will take one of the two drugs for 8 weeks. The goal is…
Matched conditions: REFLUX ESOPHAGITIS
Phase: NA • Sponsor: Asian Institute of Gastroenterology, India • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New acid blocker vonaprazan takes on esomeprazole in reflux healing showdown
Disease control Recruiting nowThis study compares two doses of vonaprazan (10 mg and 20 mg) with esomeprazole 40 mg for healing moderate to severe reflux esophagitis (grades B, C, or D) over 8 weeks. About 414 adults with GERD symptoms for at least 4 weeks will be randomly assigned to one of the three groups.…
Matched conditions: REFLUX ESOPHAGITIS
Phase: NA • Sponsor: Asian Institute of Gastroenterology, India • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC